Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Klempner, Samuel J.
Quintanilha, Julia C. F. C. F.
Emmett, Matthew
Graf, Ryon
Schrock, Alexa Betzig
Tukachinsky, Hanna
Oxnard, Geoffrey R.
Myer, Parvathi
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Fdn Med Inc, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Albert Einstein Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [21] The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
    Song, Yan
    Qu, Tao
    Zhang, Honggang
    Sun, Yongkun
    Cui, Chengxu
    Chi, Yihebali
    Zhang, Wen
    Wang, Xingyuan
    Yang, Lin
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6199 - 6205
  • [22] Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
    Harrold, Emily
    Keane, Fergus
    Sinopoli, Jenna Cohen
    Diaz, Luis A.
    Cercek, Andrea
    Yaeger, Rona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 190 - 190
  • [23] Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study
    Qu, Wang
    Liu, Zimin
    Zhu, Liangjun
    Chen, Xiaobing
    Liu, Bo
    Zhao, Yun-Bo
    Yan, Hao
    Qu, Xiujuan
    Li, Shengmian
    Zang, Ai-Min
    Jiang, Zhichao
    Sun, Yongkun
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts)
    Schirripa, Marta
    Loupakis, Fotios
    Cremolini, Chiara
    Morvillo, Manfredi
    Bergamo, Francesca
    Zoratto, Federica
    Salvatore, Lisa
    Antoniotti, Carlotta
    Marmorino, Federica
    Sensi, Elisa
    Lupi, Cristiana
    Fontanini, Gabriella
    De Gregorio, Veronica
    Giannini, Riccardo
    Basolo, Fulvio
    Masi, Gianluca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
    Agg, Himani
    Han, Yimei
    Cui, Zhanglin Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [26] Real-world study of cetuximab used every other week versus weekly in US patients with metastatic colorectal cancer (mCRC).
    Lamy, Francois-Xavier
    Batech, Michael
    Salim, Shaista
    Boutmy, Emmanuelle
    Pescott, Chris
    Ronga, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
    Cappuzzo, Federico
    Sacconi, Andrea
    Landi, Lorenza
    Ludovini, Vienna
    Biagioni, Francesca
    D'Incecco, Armida
    Capodanno, Alessandra
    Salvini, Jessica
    Corgna, Enrichetta
    Cupini, Samanta
    Barbara, Cecilia
    Fontanini, Gabriella
    Crino, Lucio
    Blandino, Giovanni
    CLINICAL COLORECTAL CANCER, 2014, 13 (01) : 37 - U62
  • [28] Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts)
    Sahin, Ibrahim Halil
    Chen, Wanqi H.
    Chen, Zhengjia
    Akce, Mehmet
    Alese, Olatunji B.
    Shaib, Walid Labib
    El-Rayes, Bassel F.
    Wu, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer
    Miotke, Laura
    Norton, Carter
    Nevala-Plagemann, Christopher Duane
    Florou, Vaia
    Rubnitz, Zach
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Comprehensive analysis of egfr and its downstream pathways deregulation identifies the vast majority of metastatic colorectal cancer (mCRC) patients resistant to anti-egfr monoclonal antibodies (MoAbs)
    Frattini, M.
    Molinari, F.
    De Dosso, S.
    Martin, V
    Crippa, S.
    Saletti, P.
    Mazzucchelli, L.
    VIRCHOWS ARCHIV, 2009, 455 : 46 - 46
12345